dc.contributor.author | Bernal, Teresa | |
dc.contributor.author | Pardavila, Estefania V. | |
dc.contributor.author | Bonastre, Juan | |
dc.contributor.author | Jarque, Isidro | |
dc.contributor.author | Borges Sa, Marcio | |
dc.contributor.author | Bargay Lleonart, Joan | |
dc.contributor.author | Ignacio Ayestaran, Jose | |
dc.contributor.author | Insausti, Josu | |
dc.contributor.author | Marcos, Pilar | |
dc.contributor.author | Gonzalez-Sanz, Victor | |
dc.contributor.author | Martinez-Camblor, Pablo | |
dc.contributor.author | Albaiceta, Guillermo M. | |
dc.date.accessioned | 2024-07-03T11:01:10Z | |
dc.date.available | 2024-07-03T11:01:10Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Bernal T, Pardavila EV, Bonastre J, Jarque I, Borges Sa M, Bargay Lleonart J, et al. Survival of hematological patients after discharge from the intensive care unit: a prospective observational study. Crit Care. 2013;17(6):R302. | en |
dc.identifier.issn | 1466-609X | |
dc.identifier.other | http://hdl.handle.net/20.500.13003/11410 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19937 | |
dc.description.abstract | Introduction: Although the survival rates of hematological patients admitted to the ICU are improving, little is known about the long-term outcome. Our objective was to identify factors related to long-term outcome in hematological patients after ICU discharge. Methods: A prospective, observational study was carried out in seven centers in Spain. From an initial sample of 161 hematological patients admitted to one of the participating ICUs during the study period, 62 were discharged alive and followed for a median time of 23 (1 to 54) months. Univariate and multivariate analysis were performed to identify the factors related to long term-survival. Finally, variables that influence the continuation of the scheduled therapy for the hematological disease were studied. Results: Mortality after ICU discharge was 61%, with a median survival of 18 (1 to 54) months. In the multivariate analysis, an Eastern Cooperative Oncology Group score (ECOG) >2 at ICU discharge (Hazard ratio 11.15 (4.626 to 26.872)), relapse of the hematological disease (Hazard ratio 9.738 (3.804 to 24.93)) and discontinuation of the planned treatment for the hematological disease (Hazard ratio 4.349 (1.286 to 14.705)) were independently related to mortality. Absence of stem cell transplantation, high ECOG and high Acute Physiology and Chronic Health Evaluation II (APACHE II) scores decreased the probability of receiving the planned therapy for the hematological malignancy. Conclusions: Both ICU care and post-ICU management determine the long-term outcome of hematological patients who are discharged alive from the ICU. | en |
dc.description.sponsorship | GMA is the recipient of a grant from Instituto de Salud Carlos III (Intensificacion de la actividad investigadora, INT 12/007). Instituto Universitario de Oncologia del Principado de Asturias (IUOPA) is supported by Obra Social Cajastur. The study was approved by the Regional Ethics Committee of Principado de Asturias (Oviedo, Spain), Clinical Research Ethics Committee of the Hospital La Fe (Valencia, Spain), Clinical Research Ethics Committee of Islas Baleares (Mallorca, Spain), Regional Ethics Committee of Aragon (Zaragoza, Spain), Clinical Research Ethics Committee of Navarra (Pamplona, Spain) and Clinical Research Ethics Committee of Hospital Germans Trias i Pujol (Badalona, Spain). | es_ES |
dc.language.iso | eng | en |
dc.publisher | BioMed Central (BMC) | en |
dc.rights.uri | https://creativecommons.org/licenses/by/2.0/ | * |
dc.subject.mesh | Decision Trees | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Hematologic Diseases | * |
dc.subject.mesh | Neutropenia | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Prognosis | * |
dc.subject.mesh | Multiple Organ Failure | * |
dc.subject.mesh | Recurrence | * |
dc.subject.mesh | Intensive Care Units | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | Prospective Studies | * |
dc.subject.mesh | APACHE | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | Risk Factors | * |
dc.subject.mesh | Medication Adherence | * |
dc.subject.mesh | Respiration, Artificial | * |
dc.subject.mesh | Patient Discharge | * |
dc.subject.mesh | Survival Rate | * |
dc.title | Survival of hematological patients after discharge from the intensive care unit: a prospective observational study | en |
dc.type | research article | en |
dc.rights.license | Attribution 2.0 Generic | * |
dc.identifier.pubmedID | 24377481 | es_ES |
dc.format.volume | 17 | es_ES |
dc.format.number | 6 | es_ES |
dc.format.page | R302 | es_ES |
dc.identifier.doi | 10.1186/cc13172 | |
dc.identifier.e-issn | 1364-8535 | es_ES |
dc.relation.publisherversion | https://dx.doi.org/10.1186/cc13172 | en |
dc.identifier.journal | Critical Care | es_ES |
dc.rights.accessRights | open access | en |
dc.subject.decs | Tasa de Supervivencia | * |
dc.subject.decs | APACHE | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Insuficiencia Multiorgánica | * |
dc.subject.decs | Unidades de Cuidados Intensivos | * |
dc.subject.decs | Masculino | * |
dc.subject.decs | Enfermedades Hematológicas | * |
dc.subject.decs | Árboles de Decisión | * |
dc.subject.decs | Cumplimiento de la Medicación | * |
dc.subject.decs | Factores de Riesgo | * |
dc.subject.decs | Humanos | * |
dc.subject.decs | Persona de Mediana Edad | * |
dc.subject.decs | Recurrencia | * |
dc.subject.decs | Estudios Prospectivos | * |
dc.subject.decs | Neutropenia | * |
dc.subject.decs | Pronóstico | * |
dc.subject.decs | Alta del Paciente | * |
dc.subject.decs | Respiración Artificial | * |
dc.identifier.scopus | 2-s2.0-84891349597 | |
dc.identifier.wos | 332293100001 | |
dc.identifier.pui | L52941881 | |